Dkk

New Survey Highlights the Significant Impact of the Economic Downturn on Europe's Sleep

...d development, production, marketing and sale of drugs for the treatment of psychiatric and neurological disorders. In 2008, the company's revenue was dkk 11.3 billion (approximately EUR 1.5 billion or USD 2.2 billion). The number of employees is approximately 5,300 globally. For further information, ple...

Genmab Announces 2008 First Half Year Results

...ed the following results: Genmab's revenues were dkk 277 million (USD 59 million) for the first half of...0 million (USD 59 million). An operating loss of dkk 471 million (USD 100 million). This compares to an operating loss of dkk 119 million (USD 25 million) reported for the corr...

Novo Nordisk Increased Net Profit by 32% in 2007

...ectors will propose a 29% increase in dividend to USD 0.83 per share of dkk 1. The ongoing share repurchase program has been increased to USD 3.0 ...lated to USD in this release, using the average exchange rate of USD 1.00 = dkk 5.44371 About Novo Nordisk Novo Nordisk is a healthcare company with an...

Genmab Initiates Ofatumumab Phase II Study in Diffuse Large B-Cell Lymphoma

...n the study which is being conducted under Genmab's collaboration with GlaxoSmithKline (GSK). Genmab will receive a milestone payment of approximately dkk 87.2 million from GSK upon treatment of the first patient in the study, expected in the near future. Ofatumumab is an investigational, fully human, ...

Dkk in Medical Technology

Genmab Reaches Milestone in Ofatumumab Collaboration

...lopment milestone for ofatumumab (HuMax-CD20(R)) under the terms of its collaboration with GlaxoSmithKline (GSK). A milestone payment of approximately dkk 29 million (approximately USD 6 million) was triggered by treatment of the first patient participating in the Phase II study of ofatumumab for the tre...

Top Line Results of Phase III Study in Acute Ischemic Stroke (DIAS-2) Do Not Demonstrate Difference Between Desmoteplase and Placebo

...d development, production, marketing and sale of drugs for the treatment of psychiatric and neurological disorders. In 2006, the company's revenue was dkk 9.2 billion (approximately EUR 1.2 billion or USD 1.6 billion). The number of employees is approximately 5,300 globally. For further information, plea...

Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression

...d development, production, marketing and sale of drugs for the treatment of psychiatric and neurological disorders. In 2006, the company's revenue was dkk 9.2 billion (approximately EUR 1.2 billion or USD 1.6 billion). The number of employees is approximately 5,300 globally. For further information, plea...

Cipralex demonstrates superiority to duloxetine for acute treatment of depression in new study

...ent, production, marketing and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders. In 2006, the company's revenue was dkk 9.2 billion (approximately EUR 1.2 billion or USD 1.6 billion). The number of employees is approx. 5300 globally. For more information, please visit <...

Dkk in Biological News

Enhanced quality of 'LIFE' through Nordic food

...rofessor Arne Astrup from LIFE, who is also the President of the International Association for the Study of Obesity (IASO), has received a donation of dkk 100 million (EUR 13.3 million) from the Nordea Foundation to fund a wide-reaching research project that will strengthen public health by focussing on ...

Donation for new Center for Pharmaceutical Nanotechnology and Nanotoxicology

...oein Moghimi (Professor of Biopharmacy and Nanomedicine, Department of Pharmaceutics and Analytical chemistry) and colleagues have received 28 million dkk (approximately 3.75 million Euros) from the Danish Council for Strategic Research (DSF) to set The Centre for Pharmaceutical Nanotechnology and Nanoto...

F-MARC funds more 'soccer and health' research

...e style-related diseases. The studies were conducted well and the submission process is running as scheduled and F-MARC has now donated additional dkk 1 million to more research lead by Professor Peter Krustrup and his colleague Professor Jens Bangsbo from the research group, "Integrated Physiology" ...

The Danisco Award 2008 goes to D.Sc. Barbara Ann Halkier from Faculty of Life Sciences, Copenhagen

...g efforts to improve foods or as a means of financing food improvement projects. The Danisco Award was first granted in 2002. It represents a value of dkk 250,000 and is one of the biggest Danish prizes within biotechnology. Barbara Ann Halkier and her research group have identified and characterized a...

Dkk in Biological Technology

Santaris Pharma - Interim Report for the Period 1 January to 30 June 2009

...ealised in the 2nd quarter of 2009 was 21,6m dkk (2,9m EUR) compared to 29,8m dkk (4,0m EUR) in the 2nd quarter of 2008. ..., 2009 the capital resources totalled 175,4m dkk (23,6m EUR). - In Q2 the SPC3649 compound tar...

Bavarian Nordic Announces its Interim Report for the Period 1 January to 31 March 2009

...arter of 2009 Bavarian Nordic generated revenue of dkk 17 million and recorded a loss before tax of dkk 83 million. The expectations for the financial res...r 2009 are maintained at revenues in the region of dkk 375 million, and a pre-tax loss in the region of...

EnWave Announces Collaboration and Initial Testing Results with Danisco AS

...portunities with Danisco". With 7,200 employees operating from more than 80 locations in the world, Danisco reported annual revenues of 18.7 billion dkk (US$3.1 billion) in its 2007/2008 year end results. The Danish group is a global leading supplier of cultures and probiotics for food, supplements and...

Bavarian Nordic Publishes its Annual Results 2008

... Bavarian Nordic's revenue for the year 2008 was dkk 209 million with a loss before tax of dkk 183 million, which was in line with the Company's ... 2008, net free cash and cash equivalents stood at dkk 796 million. For 2009, Bavarian Nordic expects rev...

Novozymes Reports Strong 2008 Results

... satisfactory. Growth outlook for 2009 of 8-13% in dkk in an uncertain market. Strong long-term trends le... local currencies (LCY), 10% in DKK, ending at dkk 8,146m - Sales growth of 5% in LCY and 10% in dkk in the fourth quarter - Operating profit of...

Interim Report for the Period 1 January - 30 September 2008 (Unaudited)

...revises its 2008 total year guidance of revenue of dkk 140-150 million to now dkk 120-130 million. As a result, a net loss of dkk 115-125 is now anticipated compared to previous ex...

Genmab Announces Results for the First Nine Months of 2008

...ed the following results: Genmab's revenues were dkk 667 million (USD 128 million) for the nine month p...same period of 2007, Genmab recognized revenues of dkk 356 million (USD 68 million). An operating loss of dkk 508 million (USD 97 million). This compares to an ...

Genmab Reaches Milestone in Ofatumumab Collaboration

...e sixth milestone for ofatumumab (HuMax-CD20(R)) under the terms of its collaboration with GlaxoSmithKline (GSK). A milestone payment of approximately dkk 29 million (approximately USD 5.6 million) was triggered by the first patient receiving treatment in the ofatumumab Phase I study in relapsed/refracto...

Exiqon A/S Today Announces a Grant of License to Roche Diagnostics

... outlook for 2008 including an expected revenue of dkk 140-150 million in 2008 including both research pr...onding to full year revenues including Oncotech of dkk 150-160 million and a net loss for the year 2008 of dkk 100-115 including...

MediCult Acquires US-Based MidAtlantic Diagnostics to Further Strengthen ART Presence

...gnostics, Inc., a US supplier of ART products, for dkk 78,6 million (USD 15,5 million). MidAtlantic Dia...ion) and deferred payments over a 3 year period of dkk 30 million (USD 6 million) in cash and dkk 2,5 million (USD 0,5 million) in MediCult shares. ...